Company Overview
Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.
Recent News
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
Stock Overview
06/01/2026 04:09 PM EDT
Investor Relations
Propanc Biopharma, Inc.
T: +61-03-9882-6723
irteam@propanc.com